On 2014 Jun 05, Swapnil Hiremath commented:

This article was discussed on May 27th 2014 on the open online nephrology journal club, #NephJC, on twitter. An introductory comment is available on the eAJKD blog here and also on the NephJC website. It was quite a spirited discussion, with participation from nephrologists, cardiologists, electrophysiogists and more. A transcript and a storify'd version of the tweetchat is available at the same NephJC link and also from the Nephrology-on-demand editor here.

On June 3rd, there was a Google Hangout on air, between the NephJC editors, Dr John Mandrola and Dr George Bakris, one of the principal investigators of the trial,which can be viewed on Youtube.

The highlights of the tweetchat were: 1. Symplicity HTN 3 was a great study and the investigators and sponsors were to be commended for carrying out this astutely designed trial, which overcame issues related to regression to the mean, placebo effect and Hawthorne effect. 2. There were some intriguing signals, such as the differential effect based on race, the role of aldosterone antagonists, and technical aspects which should be pursued in future studies. 3. Renal denervation remains an exciting innovation, though carefully designed studies, with emphasis on patient selection, mechanistic and technical aspects and long term safety and efficacy need to be conducted to help delineate the exact role of renal denervation will be in the therapy of hypertension.

Interested individuals can track and join in the conversation by following @NephJC or #NephJC, or visit the webpage at www.NephJC.com.

On 2014 Jun 05, Swapnil Hiremath commented:

This article was discussed on May 27th 2014 on the open online nephrology journal club, #NephJC, on twitter. An introductory comment is available on the eAJKD blog here and also on the NephJC website. It was quite a spirited discussion, with participation from nephrologists, cardiologists, electrophysiogists and more. A transcript and a storify'd version of the tweetchat is available at the same NephJC link and also from the Nephrology-on-demand editor here.

On June 3rd, there was a Google Hangout on air, between the NephJC editors, Dr John Mandrola and Dr George Bakris, one of the principal investigators of the trial,which can be viewed on Youtube.

The highlights of the tweetchat were: 1. Symplicity HTN 3 was a great study and the investigators and sponsors were to be commended for carrying out this astutely designed trial, which overcame issues related to regression to the mean, placebo effect and Hawthorne effect. 2. There were some intriguing signals, such as the differential effect based on race, the role of aldosterone antagonists, and technical aspects which should be pursued in future studies. 3. Renal denervation remains an exciting innovation, though carefully designed studies, with emphasis on patient selection, mechanistic and technical aspects and long term safety and efficacy need to be conducted to help delineate the exact role of renal denervation will be in the therapy of hypertension.

Interested individuals can track and join in the conversation by following @NephJC or #NephJC, or visit the webpage at www.NephJC.com.